Treatment strategies to resectable metachronous colorectal liver metastases after adjuvant oxaliplatin-based chemotherapy for primary colorectal cancer.

Date publication

avril 2022

Journal

Journal of surgical oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PESSAUX Patrick

Tous les auteurs :
Julio C, Benoist S, Allard MA, Navarro F, Pessaux P, Sa Cunha A, Brouquet A,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35397122

Résumé

outcome of patients who develop resectable metachronous colorectal liver metastases (CLM) after adjuvant oxaliplatin-based chemotherapy for Stage III colorectal cancer (CRC) is not well defined and the value of preoperative chemotherapy is controversial.

Mots clés

hepatic recurrence, liver resection, metachronous, preoperative chemotherapy

Référence

J Surg Oncol. 2022 Apr 9;: